SCHEMBL29919980

SCHEMBL29919980

COc1c(Br)ccc2[nH]c(=O)oc(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 6/20 0.41
F2 P00734 1/20 0.38
CFD P00746 1/20 0.38
MAOA P21397 5/20 0.36
MAOB P27338 5/20 0.36
CREBBP Q92793 1/20 0.36
NOS1 P29475 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
TSHR P16473 1/20 0.35
PPARG P37231 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NOS2 P35228 2/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
MAPT P10636 1/20 0.33
NOS3 P29474 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3985564 1.00 AR (0.41) ARF2CFDMAOAMAOB
SCHEMBL4490244 0.83 AR (0.45) ARF2CFDMAOAMAOB
SCHEMBL1319411 0.83 AR (0.44) ARF2CFDMAOAMAOB
SCHEMBL31457779 0.81 CREBBP (0.38) ARMAOAMAOBCREBBPNOS1
SCHEMBL20704837 0.76 ALDH1A1 (0.46) MAOASMN1; SMN2ALDH1A1TSHRPPARG
SCHEMBL3981208 0.76 F2 (0.41) ARF2CFDMAOAMAOB
SCHEMBL4491356 0.72 NOS1 (0.42) ARF2CFDMAOAMAOB
SCHEMBL14361975 0.72 ALDH1A1 (0.44) ARMAOAMAOBSMN1; SMN2ALDH1A1
SCHEMBL3498795 0.71 F2 (0.52) ARF2CFDMAOAMAOB
SCHEMBL1559364 0.71 ABCG2 (0.54) ARF2CFDMAOAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120004861-A Allosteric EGFR inhibitors and methods of use thereof 达纳-法伯癌症研究所股份有限公司 2025-05-16 CN disclosed
CN-115066240-A Allosteric EGFR inhibitors and methods of use thereof 达纳-法伯癌症研究所股份有限公司 2022-09-16 CN disclosed